Target intelligence / Profile preview

Tripartite motif-containing protein 25 (TRIM25)

Target
TRIM25
Molecular classification
Enzyme, Ubiquitin E3 ligase, ISG15 E3 ligase, Zinc finger protein
01

Overview

Tripartite motif-containing protein 25 (TRIM25) is a cytoplasmic E3 ubiquitin ligase enzyme that belongs to the TRIM family, characterized by a RING domain, one or two B-box domains, a coiled-coil domain, and a C-terminal PRY/SPRY domain. It plays central roles in antiviral innate immunity primarily through ubiquitination of proteins such as RIG-I, a key sensor of viral RNA, leading to activation of the type I interferon pathway. TRIM25 also acts as an E3 ligase for ISG15, mediates ISGylation, and has RNA-binding activity important for its antiviral function. The protein is upregulated by estrogen and implicated in breast and ovarian cancers, as well as immune responses against viral infection, cancer progression, and inflammation. Viral proteins such as influenza NS1 interact with TRIM25 to evade host immune response by inhibiting RIG-I ubiquitination. TRIM25 is structurally complex: its RING domain enables E3 ligase activity, its CCD promotes dimerization, and the PRY/SPRY domain binds substrates such as RIG-I and MAVS. Its roles in ubiquitination, immune defense, and oncogenesis make it of therapeutic interest, though no approved drugs specifically target TRIM25 in the clinical setting.

Other names
EFP (Estrogen-responsive finger protein)RNF147ZNF147Zinc finger protein 147RING finger protein 147RING-type E3 ubiquitin transferase TRIM25Tripartite motif protein TRIM25Ubiquitin/ISG15-conjugating enzyme TRIM25Z147
02

Mechanism of action

Ubiquitination of target proteins (e.g., RIG-I) via Lys63- and Lys48-linked polyubiquitin chains; Conjugation of ISG15 (ISGylation) to target proteins

03

Biological functions

UbiquitinationISGylationInnate immune responseAntiviral defenseCell proliferationCell cycle regulationProtein stabilizationmRNA translocation
04

Disease associations

CancerInfectionInflammationAntiviral immunity
05

Safety considerations

None clearly established; modulation could affect immune homeostasis and oncogenic pathways
06

Interacting drugs

None explicitly identified in the current literature or search results
07

Biomarkers

None reported as clinically validated

Beyond the preview

Go deeper on Tripartite motif-containing protein 25 (TRIM25).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tripartite motif-containing protein 25 (TRIM25).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call